FDA Approves Lilly’s Amyloid-Targeting Alzheimer’s Therapy, Four Other Drugs

The FDA on Tuesday approved Kisunla (donanemab-azbt), Eli Lilly’s once-monthly injection for adults with early symptomatic Alzheimer’s disease (AD), along with earlier approvals of four other drugs for various conditions.
Source: Drug Industry Daily